Pituitary adenylate cyclase activating-peptide and its receptor antagonists in development of acute pancreatitis in rats

doi:10.3748/wjg.v11.i4.538

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2417)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-8) series.

Item

Count

PDF

200

HTML

2083

Tables (1-8)

134

Sum=2417

Jan 28, 2005 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Jan 28, 2005; 11(4): 538-544
Published online Jan 28, 2005. doi: 10.3748/wjg.v11.i4.538

Table 1 Ascites/peritoneal fluid and their gross appearance (action of PACAP) (mean±SE).

Group	Volume ofascites (mL)	Ascites amylase(IU/L)	Nucleated cells in ascites (×10⁸/L)	Saponifi -cation (n)	Hemorr -hage (n)
Control		213±44/7	1.71±1.02/9
Caerulein-induced pancreatitis		39075±50341/3	7.54±2.85/4^a
Sodium taurocholate-induced pancreatitis	3.55±1.86/12	11 463±5 486/10^a	2.9±3.06/8	2	3
PACAP 5 μg/kg
PACAP 10 μg/kg
PACAP 15 μg/kg
PACAP 30 μg/kg			3.26±1.89/6
Sodium taurocholate+PACAP 5 μg	2.33±0.82/6	26917±11145/6^a	2.3±0.98/6	2/6	4/6
Sodium taurocholate+PACAP 10 μg	4.77±2.44	5956±3546/8^a	1.76±1.02/11	7	11
Caerulein+PACAP 15 μg	0.55±0.96	926/1		1	1
Caerulein+PACAP 30 μg	0.91±0.83	63918±82884/8	1.73±1.23/8	1	3

^aP<0.05 vs normal control.

Table 2 Histological scoring (action of PACAP) (mean±SE).

Group	Hemorrhage	Parenchymal necrosis	Vacuolization	Inflammation
Caerulein-induced pancreatitis			1.67±0.60	2.5±0.22
Sodium taurocholate-induced pancreatitis	1.5±0.67	2.5±0.49	0.5±0.49	3
PACAP 5 μg			0.33±0.33	0.17±0.17
PACAP 10 μg		0.17±0.17	0.67±0.49	1.33±0.61
PACAP 15 μg			0.33±0.33	1.5±0.67
PACAP 30 μg		0.17±0.17	0.83±0.54	1.5±0.5
Sodium taurocholate+PACAP 5 μg	1.67±0.49	2.67±0.33	2±0.63	3
Sodium taurocholate +PACAP 10 μg	2±0.63	2.5±0.5	1.5±0.56	3
Caerulein+PACAP 15 μg	1.5±0.5	2±0.63	2.5±0.22	1.67±0.60
Caerulein+PACAP 30 μg	1.83±0.60	2.17±0.31	2.33±0.49	2.17±0.48

Table 3 Dry weight/wet weight ratio of pancreas and serum amylase (action of PACAP) (mean±SE).

Group	Pancreatic dry weight/wet weight ratio (%)	Serum amylase (IU/L)
Normal control	29.21±5.657	520.8±163.27
Caerulein-induced pancreatitis	21.83±3.013^a	3699.33±3826.56^a
Sodium taurocholate-induced pancreatitis	17.52±1.505^a	3690.87±2277.99^a
PACAP 5 μg	25.86±1.974	818.09±404.76^a
PACAP 10 μg	24.81±1.312	675.55±271.44
PACAP 15 μg	23.88±2.532	671.36±151.98^a
PACAP 30 μg	25.17±0.897	899.09±474.49
Sodium taurocholate+PACAP 5 μg	19.18±2.102^a	2944.33±1182.47^a
Sodium taurocholate+PACAP 10 μg	20.87±5.597^a	1986.91±710.97^a
Caerulein+PACAP 15 μg	17.66±4.652^a	4053.55±2164.07^a
Caerulein+PACAP 30 μg	13.45±2.045^a	5243.46±3769.73^a

^aP<0.05 vs normal control.

Table 4 ELISA for PACAP in pancreas and duodenum (mean±SE).

Group	Relative concentrations
Group	In pancreas	In duodenum
Normal control	0.02215±0.01123 (n = 4)	0.000335±0.000074 (n = 5)
Caerulein-induced AP	12.0712±8.40536 (n = 4)^a	0.003797±0.002301 (n = 5)^a
Sodium taurocholate-induced AP	0.2799±0.22932 (n = 4)^a	0.001564±0.000529 (n = 4)^a

^aP<0.05 vs normal control.

Table 5 Ascites and its gross appearance (effect of PACAP receptor antagonists) (mean±SE).

Group	Volume of ascites (mL)	Ascites amylase(IU/L)	Nucleated cell countof ascites (×10⁸/L)	Saponi-fication (n)	Hemorr-hage (n)
Normal control		213±44/7	1.71±1.02/9
Caerulein-induced pancreatitis		39075±50341/3	7.54±2.85/4^a
Sodium taurocholate-induced pancreatitis	3.55±1.86/12	11463±5486/10^a	2.9±3.06/8	2/12	3/12
10 μg PACAP6-27		2000±1273/2	3.43±1.22/6^a
100 μg PACAP6-27		600±283/2	1.39±0.98/2
Caerulein+10 μg PACAP6-27		5725±3104/4^a	7.04±4.93/5^a
Caerulein +100 μg PACAP6-27	3/1	90250±94964/2^a	1.53±0.82/2
Sodium taurocholate+10 μg PACAP6-27	2.58±0.86/6	49467±45529/6^a	2.35±1.81/6	1/6	3/6
Sodium taurocholate+100 μg PACAP6-27	3.42±1.99/6	64083±40650/6^a	3.44±1.7/6^a	4/6	2/6
10 μg (4-Cl-D-Phe6, Leu17) VIP		750±495/2^a	5.52±2.38/4^a
100 μg (4-Cl-D-Phe6, Leu17) VIP		201	3.4/1
Caerulein+10 μg (4-Cl-D-Phe6, Leu17) VIP		6100±1697/2^a	5.38±2.17/5^a
Caerulein+100 μg (4-Cl-D-Phe6, Leu17) VIP		217	1.06±0.51/3
Sodium taurocholate+10 μg (4-Cl-D-Phe6, Leu17) VIP	2.25±0.88/6	32700±13611/6^a	2.25±0.86/6		3/6
Sodium taurocholate+100 μg (4-Cl-D-Phe6, Leu17) VIP	4.17±1.13/6	68817±46943/6^a	2.51±1.5/4		2/6

^aP<0.05 vs normal control.

Table 6 Pancreatic dry weight/wet weight ratio and serum amylase (effect of PACAP receptor antagonists) (mean±SE).

Group	Dry weight/wet weight ratio (%)	Serum amylase (IU/L)
Normal control	29.21±5.657	520.8±163.27
Caerulein-induced pancreatitis	21.83±3.013^a	3699.33±3826.56^a
Sodium taurocholate-induced pancreatitis	17.52±1.505^a	3690.87±2277.99^a
10 μg PACAP6-27	25.25±2.286^a	1464.33±265.6^a
100 μg PACAP6-27	26.21±2.577	1692.17±312.18^a
Caerulein+10 μg PACAP6-27	22.75±3.523^a	2484.33±1459.64^a
Caerulein+100 μg PACAP6-27	21.4±4.152^a	6485.5±3352.84^a
Sodium taurocholate+10 μg PACAP6-27	20.81±3.94^a	5026.83±3697.35^a
Sodium taurocholate+100 μg PACAP6-27	17.99±3.594^a	7667.67±4270.93^a
10 μg (4-Cl-D-Phe6, Leu17) VIP	25.61±2.389^a	1 337.17±314.02^a
100 μg (4-Cl-D-Phe6, Leu17) VIP	26.77±1.377	1781±527.65^a
Caerulein+10 μg (4-Cl-D-Phe6, Leu17) VIP	24.33±0.939^a	2875.33±582.98^a
Caerulein+100 μg (4-Cl-D-Phe6, Leu17) VIP	22.36±2.13^a	8307.83±2003.41^a
Sodium taurocholate+10 μg (4-Cl-D-Phe6, Leu17) VIP	16.89±1.18^a	4684.33±993.55^a
Sodium taurocholate+100 μg (4-Cl-D-Phe6, Leu17) VIP	18.71±4.048^a	7264.67±2834.91^a

^aP<0.05 vs normal control.

Table 7 Histological scoring (effect of PACAP receptor antagonists) (mean±SE).

Group	Hemorrhage	Parenchymal necrosis	Vacuolization	Inflammatory infiltration
Caerulein-induced pancreatitis			1.67±0.60	2.5±0.22
Sodium taurocholate-induced pancreatitis	1.5±0.67	2.5±0.49	0.5±0.49	3
10 μg PACAP6-27				1.5±0.5
100 μg PACAP6-27				0.83±0.54
Caerulein+10 μg PACAP6-27	0.83±0.54	0.17±0.17	1.83±0.60	2.5±0.5
Caerulein+100 μg PACAP6-27	1.67±0.49	1±0.52	2.17±0.31	2.5±0.22
Sodium taurocholate+10 μg PACAP6-27	1.5±0.67	3	1.33±0.61	3
Sodium taurocholate+100 μg PACAP6-27	1.5±0.5	2.83±0.17	2±0.52	3
10 μg (4-Cl-D-Phe6, Leu17) VIP			0.33±0.33	2±0.63
100 μg (4-Cl-D-Phe6, Leu17) VIP			1±0.63	1.67±0.60
Caerulein+10 μg (4-Cl-D-Phe6, Leu17) VIP	0.17±0.17	0.17±0.17	0.67±0.40	2±0.51
Caerulein+100 μg (4-Cl-D-Phe6, Leu17) VIP	0.33±0.33	1.67±0.49	2.17±0.48
Sodium taurocholate+10 μg (4-Cl-D-Phe6, Leu17) VIP	1.5±0.56	2.5±0.49	1.17±0.60	3
Sodium taurocholate+100 μg (4-Cl-D-Phe6, Leu17) VIP	1.5±0.67	2.33±0.33	1.83±0.60	3

Table 8 Functional capillary densities of pancreas (mean±SE).

Group	FCD (cm^-1)	Calibrated FCD (cm^-1)
Normal control	22.93±5.189
Caerulein-induced pancreatitis	25.71±3.398^a	34.4
Sodium taurocholate-induced pancreatitis	21.9±5.681	36.51
PACAP 5 μg	21.68±4.268	24.49
PACAP 10 μg	19.52±3.837^a	22.98
PACAP 15 μg	19.6±4.949^a	23.97
PACAP 30 μg	18.56±6.021^a	21.53
Sodium taurocholate+PACAP 10 μg	18.71±3.383^a	26.19
Caerulein+PACAP15 μg	22.68±3.62	37.51
Caerulein+PACAP 30 μg	18.28±3.772^a	39.7

^aP<0.05 vs normal control.

Citation: Chen YD, Zhou ZG, Wang Z, Gao HK, Yan WW, Wang C, Zhao GP, Peng XH. Pituitary adenylate cyclase activating-peptide and its receptor antagonists in development of acute pancreatitis in rats. World J Gastroenterol 2005; 11(4): 538-544
URL: https://www.wjgnet.com/1007-9327/full/v11/i4/538.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i4.538